GSK punts a failed car­dio drug to a biotech start­up — which has a new de­vel­op­ment strat­e­gy in mind

7 years ago
Startups
R&D

Can dif­fer­ences in ge­nom­ic im­mune sys­tem sig­na­tures de­tect lung can­cer be­fore it takes hold?

7 years ago
Discovery

The biotech era in late-stage drug R&D and mar­ket­ing has ar­rived. And it looks like it’s here to stay

7 years ago
R&D

As safe­ty looms larg­er in CAR-T re­search, study high­lights how small tweaks can make it eas­i­er to use

7 years ago
R&D
Cell/Gene Tx

What’s it take to re­cruit a top drug de­vel­op­ment ex­ec out of Gilead? Stock op­tions help, a lot

7 years ago
People

Lil­ly to sell lega­cy an­tibi­otics, Ce­clor and Van­cocin, to Chi­na-based part­ner in $375M deal

7 years ago
China

Long on ideas but short on ex­pe­ri­ence? Start Codon has some cash and a place for you in the Gold­en Tri­an­gle

7 years ago
Financing

Pos­i­tive piv­otal Lil­ly da­ta set stage for Taltz ap­proval in non-ra­di­ograph­ic ax­i­al spondy­loarthri­tis

7 years ago
R&D

How bio­phar­ma com­pa­nies use NIH and vice ver­sa

7 years ago
Discovery

Three Asian MD An­der­son sci­en­tists purged in wake of NIH-di­rect­ed in­ves­ti­ga­tions on da­ta vi­o­la­tions

7 years ago
China

Seat­tle Ge­net­ics CEO Clay Sie­gal­l's comp pack­age soars to $18.1M, ri­val­ing Big Phar­ma chiefs

7 years ago
People

Pfiz­er on­col­o­gy R&D ex­ec heads to Aduro as new CMO; Army dumps Tonix re­search con­tract

7 years ago
News Briefing

As ri­vals wait in line, Mer­ck­'s Keytru­da scores ear­ly FDA nod for front­line pa­tients with the most com­mon form of ...

7 years ago
R&D
Pharma

Watch out blue­bird bio. A lit­tle biotech just got No­var­tis’ back­ing to break out of the back field and race you to ...

7 years ago
Financing
Cell/Gene Tx

Biotech vet Troy Wil­son shines a spot­light on his oligonu­cleotide start­up as Eli Lil­ly signs up for a pre­mier Big ...

7 years ago
Financing

FDA ap­proves the first gener­ic for life-sav­ing opi­oid over­dose treat­ment nalox­one that can be car­ried by un­trained ...

7 years ago
Pharma

Jeff Aron­in's start­up in­cu­ba­tor scoops ex-Alk­er­mes ex­ec Jim Robin­son for new pres­i­dent/COO role

7 years ago
People

No­var­tis' star gene ther­a­py faces po­ten­tial safe­ty is­sue fol­low­ing a re­cent in­fant death in study

7 years ago
Cell/Gene Tx

RIP tanezum­ab? Eli Lil­ly, Pfiz­er spot­light alarm­ing safe­ty da­ta for NGF pain drug in PhI­II

7 years ago
R&D

Peer Re­view: KSQ woos Beni Wolf from Blue­print with CRISPR plat­form; As­traZeneca ex­ec jumps to CNS biotech spun out ...

7 years ago
Peer Review

Gen­fit wins BTD sta­tus at FDA for its lead drug for liv­er dis­ease; Idor­sia out­lines $530M '19 spend­ing plans on ...

7 years ago
News Briefing

Two gene ther­a­py ap­provals head­line CBER’s FY 2018 re­port

7 years ago
R&D

Penn sci­en­tists cor­rect ge­net­ic flaw in mice fe­tus­es, ex­pand­ing in utero CRISPR reach to lung dis­eases

7 years ago
Discovery

Gilead-part­nered Vi­en­na-based im­munother­a­py com­pa­ny Hookipa makes Nas­daq de­but with down­sized $84M IPO

7 years ago
Financing
First page Previous page 956957958959960961962 Next page Last page
A service from the Financial Times